All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What are the initial data of dara-CyBorD in patients with extramedullary disease?

Feb 3, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Meral Beksac, Ankara University, Ankara, TR. We asked, What are the initial data of dara-CyBorD in patients with extramedullary disease?

What are the initial data of dara-CyBorD in patients with extramedullary disease?

In this podcast, Beksac discusses their poster presented at ASH 2022 entitled: Efficacy of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone for the treatment of multiple myeloma patients presenting with extramedullary disease: a European Myeloma Network study. Beksac outlines the methods and motivations for this phase II open-label study, including the unmet need for patients with para-skeletal plasmacytomas, and concludes by discussing the study results in terms of progression-free survival, safety, and efficacy, and comparing these results with the previous LYRA study.